| Literature DB >> 31664439 |
Delfina Janiri1,2, Dominik A Moser1, Gaelle E Doucet1, Maxwell J Luber1, Alexander Rasgon1, Won Hee Lee1, James W Murrough1, Gabriele Sani3,4, Simon B Eickhoff5,6, Sophia Frangou1.
Abstract
Importance: Major depressive disorder, bipolar disorder, posttraumatic stress disorder, and anxiety disorders are highly comorbid and have shared clinical features. It is not yet known whether their clinical overlap is reflected at the neurobiological level. Objective: To detect transdiagnostic convergence in abnormalities in task-related brain activation. Data Source: Task-related functional magnetic resonance imaging articles published in PubMed, Web of Science, and Google Scholar during the last decade comparing control individuals with patients with mood, posttraumatic stress, and anxiety disorders were examined. Study Selection: Following Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guidelines, articles were selected if they reported stereotactic coordinates of whole-brain-based activation differences between adult patients and control individuals. Data Extraction and Synthesis: Coordinates of case-control differences coded by diagnosis and by cognitive domain based on the research domain criteria were analyzed using activation likelihood estimation. Main Outcomes and Measures: Identification of transdiagnostic clusters of aberrant activation and quantification of the contribution of diagnosis and cognitive domain to each cluster.Entities:
Year: 2020 PMID: 31664439 PMCID: PMC6822098 DOI: 10.1001/jamapsychiatry.2019.3351
Source DB: PubMed Journal: JAMA Psychiatry ISSN: 2168-622X Impact factor: 21.596
Experiments and Samples Included in the Database
| Diagnosis | Experiments, Total No. | Patients | Healthy Individuals | ||||
|---|---|---|---|---|---|---|---|
| Sample, No. | Age, Mean (SD), y | Men, Mean (SD), % | Sample, No. | Age, Mean (SD), y | Men, Mean (SD), % | ||
| MDD | 149 | 1656 | 36.2 (9.85) | 41 (17) | 1759 | 33.7 (9.41) | 43 (15) |
| BD | 103 | 1486 | 37.9 (10.52) | 48 (21) | 1642 | 36.4 (10.26) | 47 (19) |
| PTSD | 55 | 557 | 35.0 (8.65) | 44 (40) | 574 | 34.5 (8.25) | 43 (40) |
| ANX | 60 | 808 | 29.6 (7.4) | 38 (23) | 780 | 28.96 (7.07) | 39 (23) |
Abbreviations: ANX, anxiety disorders; BD, bipolar disorder; CD, cross domain; CS, cognitive systems; MDD, major depressive disorders; NVS, negative valence systems; PVS, positive valence systems; PTSD, posttraumatic stress disorder; RDoC, research domain criteria; SP, social processes.
There were no experiments that could be mapped to the domain of arousal. Experiment indicates set of coordinates of case-control differences originating from specific task contrasts; some published articles contributed more than 1 experiment (details in the eMethods and eTables 2-5 in the Supplement).
Of the 149 MDD experiments, CS was studied in 27; NVS, 41; PVS, 43; SP, 17; and CD, 21.
Of the 103 BD experiments, CS was studied in 49; NVS, 20; PVS, 11; SP, 7; and CD, 16.
Of the 55 PTSD experiments, CS was studied in 13; NVS, 12; PVS, 1; SP, 14; and CD, 14.
Of the 60 ANX experiments, CS was studied in 2; NVS, 20; PVS, 1; SP, 15; and CD, 22.
Figure 1. Transdiagnostic Clusters of Hypoactivation in Patients Relative to Healthy Individuals
A, Activation likelihood estimation identified 3 transdiagnostic clusters of relative hypoactivation in patients centered on right inferior prefrontal cortex/insula (IFG/INS), the right inferior parietal lobule (IPL), and the right putamen. B, Percentage contribution of each research domain criteria (RDoC) to each cluster. Additional details are in eTable 7 in the Supplement.
Figure 2. Transdiagnostic Clusters of Hyperactivation in Patients Compared With Healthy Individuals
A, Activation likelihood estimation identified 3 transdiagnostic clusters of hyperactivation in the left amygdala/parahippocampal gyrus (PHG), the left thalamus, and the perigenual/dorsal anterior cingulate cortex (dACC). B, Percentage contribution of each research domain criteria (RDoC) to each cluster. Additional details are in eTable 7 in the Supplement.